Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer

Prostate

Volumn 67, Issue 2, 2007, Pages 214-225

  Norris, Alixanna M ^a   Woodruff, R D ^a   D'Agostino Jr , Ralph B ^a   Clodfelter, Jill E ^a   Scarpinato, Karin Drotschmann ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Human prostate cancer; Microsatellite instability; Mismatch repair protein; PMS2 elevation; Prognostic marker

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; MICROSATELLITE INSTABILITY; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

ADENOCARCINOMA; ADENOSINE TRIPHOSPHATASES; CARRIER PROTEINS; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE REPEATS; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846602653     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20522     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Fleshner N. Defining high-risk prostate cancer: Current status. Can J Urol 2005;12(Suppl 1):14-17.
3. Colombo P, Patriarca C, Alfano RM, Cassani B, Ceva Grimaldi G, Roncalli M, Bosari S, Coggi G, Campo B, Gould VE. Molecular disorders in transitional vs. peripheral zone prostate adenocarcinoma. Int J Cancer 2001;94:383-389.
4. Dahiya R, Lee C, McCarville J, Hu W, Kaur G, Deng G. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int J Cancer 1997;72:762-767.
5. Egawa S, Uchida T, Suyama K, Wang C, Ohori M, Irie S, Iwamura M, Koshiba K. Genomic instability of microsatellite repeats in prostate cancer: Relationship to clinicopathological variables. Cancer Res 1995;55:2418-2421.
6. Uchida T, Wada C, Wang C, Ishida H, Egawa S, Yokoyama E, Ohtani H, Koshiba K. Microsatellite instability in prostate cancer. Oncogene 1995;10:1019-1022.
7. Gao X, Wu N, Grignon D, Zacharek A, Liu H, Salkowski A, Li G, Sakr W, Sarkar F, Porter AT. High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 1994;9:2999-3003.
8. Suzuki H, Komiya A, Aida S, Akimoto S, Shiraishi T, Yatani R, Igarashi T, Shimazaki J. Microsatellite instability and other molecular abnormalities in human prostate cancer. Jpn J Cancer Res 1995;86:956-961.
9. Watanabe M, Imai H, Kato H, Shiraishi T, Ushijima T, Nagao M, Yatani R. Microsatellite instability in latent prostate cancers. Int J Cancer 1996;69:394-397.
10. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG, Thibodeau SN. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996;56:4475-4482.
11. Zhou XP, Hoang JM, Li YJ, Seruca R, Carneiro F, Sobrinho-Simoes M, Lothe RA, Gleeson CM, Russell SE, Muzeau F, Flejou JF, Hoang-Xuan K, Lidereau R, Thomas G, Hamelin R. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 1998;21:101-107.
12. Ahman AK, Jonsson BA, Damber JE, Bergh A, Emanuelsson M, Gronberg H. Low frequency of allelic imbalance at the prostate cancer susceptibility loci HPC1 and 1p36 in Swedish men with hereditary prostate cancer. Genes Chromosomes Cancer 2000;29:292-296.
13. Terrell RB, Wille AH, Cheville JC, Nystuen AM, Cohen MB, Sheffield VC. Microsatellite instability in adenocarcinoma of the prostate. Am J Pathol 1995;147:799-805.
14. Rohrbach H, Haas CJ, Baretton GB, Hirschmann A, Diebold J, Behrendt RP, Lohrs U. Microsatellite instability and loss of heterozygosity in prostatic carcinomas: Comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases. Prostate 1999;40:20-27.
15. Leach FS. Microsatellite instability and prostate cancer: Clinical and pathological implications. Curr Opin Urol 2002;12:407-411.
16. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, Barrett JC, Kolodner RD, Kunkel TA. Microsatellite instability mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 1995;55:6063-6070.
17. Yeh CC, Lee C, Dahiya R. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem Biophys Res Commun 2001;285:409-413.
18. Chen Y, Wang J, Fraig MM, Henderson K, Bissada NK, Watson DK, Schweinfest CW. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int J Oncol 2003;22:1033-1043.
19. Velasco A, Albert PS, Rosenberg H, Martinez C, Leach FS. Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol Ther 2002;1:362-367.
20. Velasco A, Albert PS, Rosenberg H, Martinez C, Leach FS. Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol Ther 2002;1:362-367.
21. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: Functions and mechanisms. Chem Rev 2006;106:302-323.
22. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, Watson DK, Schweinfest CW. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001;61:4112-4121.
23. Umemura S, Itoh J, Itoh H, Serizawa A, Saito Y, Suzuki Y, Tokuda Y, Tajima T, Osamura RY. Immunohistochemical evaluation of hormone receptors in breast cancer: Which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol 2004;12:8-13.
24. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
25. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-3090.
26. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: Functions and mechanisms. Chem Rev 2006;106:302-323.
27. Chen Y, Wang J, Fraig MM, Henderson K, Bissada NK, Watson DK, Schweinfest CW. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int J Oncol 2003;22:1033-1043.
28. Velasco A, Albert PS, Rosenberg H, Martinez C, Leach FS. Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol Ther 2002;1:362-367.
29. Umemura S, Itoh J, Itoh H, Serizawa A, Saito Y, Suzuki Y, Tokuda Y, Tajima T, Osamura RY. Immunohistochemical evaluation of hormone receptors in breast cancer: Which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol 2004;12:8-13.
30. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: Functions and mechanisms. Chem Rev 2006;106:302-323.
31. Cunha GR, Chung LW. Stromal-epithelial interactions - I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J Steroid Biochem 1981;14:1317-1324.
32. Sung SY, Chung LW. Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002;70:506-521.
33. Barclay WW, Woodruff RD, Hall MC, Cramer SD. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 2005;146:13-18.
34. Konishi N, Shimada K, Ishida E, Nakamura M. Molecular pathology of prostate cancer. Pathol Int 2005;55:531-539.
35. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
36. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-3090.
37. De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004;74:954-964.
38. Hendriks YM, Jagmohan-Changur S, van der Klift HM, Morreau H, van Puijenbroek M, Tops C, van Os T, Wagner A, Ausems MG, Gomez E, Breuning MH, Brocker-Vriends AH, Vasen HF, Wijnen JT. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology 2006;130:312-322.
39. Worthley DL, Walsh MD, Barker M, Ruszkiewicz A, Bennett G, Phillips K, Suthers G. Familial mutations in PMS2 can cause autosomal dominant hereditary nonpolyposis colorectal cancer. Gastroenterology 2005;128:1431-1436.
40. Truninger K, Menigatti M, Luz J, Russell A, Haider R, Gebbers JO, Bannwart F, Yurtsever H, Neuweiler J, Riehle HM, Cattaruzza MS, Heinimann K, Schar P, Jiricny J, Marra G. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005;128:1160-1171.
41. Balogh GA, Russo IH, Russo J. Truncation of the mismatch repair protein PMS2 during the neoplastic transformation of human breast epithelial cells in vitro. Int J Oncol 2004;25:381-387.
42. Truninger K, Menigatti M, Luz J, Russell A, Haider R, G ebbers JO, Bannwart F, Yurtsever H, Neuweiler J, Riehle HM, Cattaruzza MS, Heinimann K, Schar P, Jiricny J, Marra G. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005;128:1160-1171.
43. Nakagawa H, Lockman JC, Frankel WL, Hampel H, Steenblock K, Burgart LJ, Thibodeau SN, de la Chapelle A. Mismatch repair gene PMS2: Disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 2004;64:4721-4727.
44. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-178.
45. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, Watson DK, Schweinfest CW. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001;61:4112-4121.
46. Perinchery G, Nojima D, Goharderakhshan R, Tanaka Y, Alonzo J, Dahiya R. Microsatellite instability of dinucleotide tandem repeat sequences is higher than trinucleotide, tetranucleotide and pentanucleotide repeat sequences in prostate cancer. Int J Oncol 2000;16:1203-1209.
47. Gibson SL, Narayanan L, Hegan DC, Buermeyer AB, Liskay RM, Glazer PM. Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. Cancer Lett 2006;244:195-202.
48. Chen Jiguo, Sadowski Ivan. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci 2005; 0407069102.
49. Polager S, Kalma Y, Berkovich E, Ginsberg D. E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene 2002;21:437-446.
50. Cunha GR, Chung LW. Stromal-epithelial interactions-I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J Steroid Biochem 1981;14:1317-1324.
51. Sung SY, Chung LW. Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002;70:506-521.
52. Barclay WW, Woodruff RD, Hall MC, Cramer SD. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 2005;146:13-18.
53. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: Functions and mechanisms, Chem Rev 2006;106:302-323.
54. Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 2003;100:2420-2425.
55. Shcherbakova PV, Hall MC, Lewis MS, Bennett SE, Martin KJ, Bushel PR, Afshari CA, Kunkel TA. Inactivation of DNA mismatch repair by increased expression of yeast MLH1. Mol Cell Biol 2001;21:940-951.